CLINICAL ROLE -
Study Finds Intermittent Fasting May Offset Alzheimer Disease Risk, Support Treatment Goals
The study may serve as a foundation for future investigation regarding dietary recommendations to support the treatment of Alzheimer disease.
Hormone Therapy May Reduce Risk of Alzheimer Disease Pathology, Cognitive Decline in Women
Findings from 2 large datasets suggest hormone therapy may reduce Alzheimer risk, hippocampal atrophy, and cerebrovascular disease.
GLP-1 Agonists Show Promise in Treatment of Neurodegenerative Disorders
Significant commonalities between type 2 diabetes and neurodegenerative disorders suggest that treatments effective for one condition may benefit the other.
Brazilian Literacy Program Improves Executive Function in Low-Educated Population, Reducing Dementia Risk
Improvements were observed in both the intervention and control group, with those who had self-reported learning difficulties showing the least improvement.
Human Pluripotent Stem Cell Line Variability Supports Successful Cortical Organoid Production
Small adjustments in human pluripotent stem cell cultures and the molecule concentration patterns in the initial 5 days of differentiation are essential to “rescue” the lines.
Expert: Psychosis in Alzheimer Disease Contributes to Rapid Cognitive, Functional Decline
In addition to a rapid deterioration, psychosis in Alzheimer disease can also lead to poorer quality of life, damaged patient-caregiver relationships, and increased isolation.
Expert: The Definition of Alzheimer Disease is Shifting From Clinical to Biological
Edward B. Lee, MD, PhD, also describes how understanding Alzheimer disease requires the integration of multiple fields including genetics, pathology, epidemiology, pharmacology, and physiology.
Open-Label Trial Extension Supports Continued Long-Term Treatment With Lecanemab in Patients with Early AD
Study results demonstrated that lecanemab provided sustained benefits over 36 months, such as improved biomarker profiles and slowed cognitive decline compared with placebo.
Expert: Tau Oligomers Are a Culprit in the Spread of Alzheimer Disease Pathology
Tara Spires-Jones, DPhil, FMedSci, discusses how oligomeric tau clumps inside brain synapses, pointing to indirect evidence that it may be progressing through the brain by jumping between connections.
The CLEARMIND Trial and Clinical Implications of Lomecel-B in Alzheimer Disease
The co-founder, chief science officer, and chairman at Longeveron discusses the findings from the phase 2a trial CLEARMIND, as well as next steps to developing the therapy Lomecel-B.
The Impact of Bilingualism on Dementia: Integrating a Sociocultural and Biological Framework
Understanding and accounting for linguistic diversity is critical in diagnostics and treatment for dementia.
Expert: How Lomecel-B Stands Out in the Treatment of Alzheimer Disease
Joshua Hare describes how Lomecel-B addresses neuroinflammation, unlike other treatments which typically target amyloid disposition.
Lomecel-B CLEARMIND Phase 2a Trial Results to Be Presented at AAIC
Safety and efficacy findings on Lomecel-B will be presented at the upcoming 2024 Alzheimer’s Association International Conference, which will be held July 28 to August 1.
